Clinical Trial Companies Argue Deaths Not Linked to Trials July 21, 2016 Ziopharm Oncology is reporting that a patient died following intracranial hemorrhaging. Read More
AZ’s Tagrisso Soars in Phase 3 July 20, 2016 The candidate reached its primary endpoint of superior progression-free survival. Read More
Roche’s Blood Cancer Candidate Fails in Phase 3 July 20, 2016 Gazyva floundered in a Phase 3 trial against Rituxan. Read More
Pfizer Nabs Extended Indication for Prevnar 13 July 20, 2016 Prevnar 13 is now indicated for adults between the ages of 18 and 49. Read More
Loxo Oncology Secures Breakthrough Designation July 20, 2016 The company’s tropomyosin receptor kinase inhibitor candidate LOXO-101 scored the designation. Read More
FDA Removes Hold on Juno Therapeutics’ Cancer Trial July 19, 2016 The agency lifted its clinical hold on the company’s research after Juno pledged to alter its protocols. Read More
Sucampo Terminates Development of Cobiprostone July 18, 2016 The company pulled the plug after the candidate failed to show clinical benefit in an ongoing oral mucositis study. Read More
Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study July 18, 2016 The candidate reached all of its co-primary endpoints. Read More
Pfizer’s Sutent Meets Primary Endpoint in Pivotal Trial July 18, 2016 The candidate met its primary endpoint of prolonging disease-free survival. Read More
More Patient Deaths Reported by Clinical Trial Companies July 15, 2016 Clinical trial-related deaths have come to the fore this week following announcements from two companies about incidents during trials. Read More
Comprehensive Addiction and Recovery Act Skates Through House July 14, 2016 The report passed the House, 243-177. Read More
FDA Places Clinical Hold on Juno Trials Following Three Deaths July 14, 2016 Three patients died from cerebral edema. Read More